Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Net Income
Bottom-line profit after all expenses, interest, and taxes.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$56.21M, compared with -$36.85M a year earlier. Trailing-twelve-month net income was -$157.32M.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$220.5M (-59.8%) for the fiscal year ending Dec 2026, a step up from the -102.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$56.21M-50.4% QoQ
- Last fiscal yearDec 2025
- -$137.95M-102.9% YoY
- LTMMar 2026
- -$157.32M-70.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -52.6% | -81.7% | -29.2 pp |
| 1 year | -102.9% | -59.8% | +43.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (137.95M) USD
- Year-over-year change
- -102.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (137.95M) | -102.9% |
| FY2024 | 2024-12-31 | (68M) | -30.8% |
| FY2023 | 2023-12-31 | (51.99M) | -37.4% |
| FY2022 | 2022-12-31 | (37.85M) | — |
Net Income vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's LTM Mar 2026 net income of -$157.32M is the 4th highest of the 6 companies compared; the peer median is -$70.36M.
- Its year-over-year change of -70.4% is the 5th highest of 6, against a peer median of -26.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$40.23M | -45.6% | — | — | |
| LTM Mar 2026 | -$68.17M | -23.5% | — | — | |
| LTM Mar 2026 | -$70.36M | -26.1% | — | 44.8% | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | -$157.32M | -70.4% | — | — |
| LTM Mar 2026 | -$162.08M | -206.2% | — | 1363.9% | |
| LTM Mar 2026 | -$221.04M | -23.7% | — | — | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | -$70.36M | -26.1% | — | 704.4% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 31.31M | 30.62M | 63.62M | 125.1M |
| Selling, General & Admin | 6.34M | 9.27M | 18.77M | 30.51M |
| Operating Expenses | 37.66M | 39.89M | 82.39M | 155.6M |
| Depreciation & Amortization | 10K | 19K | 56K | 105K |
| EBITDA | (37.72M) | (51.96M) | (67.75M) | (137.63M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (37.66M) | (39.89M) | (82.39M) | (155.6M) |
| Operating Margin | — | — | — | — |
| Interest Income | 4K | 1.31M | 14.58M | 17.87M |
| Interest Expense | 112K | 0 | 0 | 0 |
| Other Income / Expenses | (188K) | (12.09M) | 14.58M | 17.87M |
| Income Before Tax | (37.84M) | (51.98M) | (67.81M) | (137.73M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1K | 5K | 187K | 217K |
| Net Income | (37.85M) | (51.99M) | (68M) | (137.95M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.73) | (1.00) | (1.25) | (2.52) |
| EPS (Diluted) | (0.73) | (1.00) | (1.25) | (2.52) |
| Weighted Avg Shares | 51.76M | 51.76M | 54.42M | 54.68M |
| Weighted Avg Shares (Diluted) | 51.76M | 51.76M | 54.42M | 54.68M |
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.